Locations:
SearchAdvertisement
FDA makes MitraClip available to more patients with mitral regurgitation
Since 2013, minimally invasive surgery for mitral valve repair has been available for patients with primary mitral regurgitation who can’t have open heart surgery. The innovative transcatheter MitraClip® device can bring relief to patients without the risk of conventional surgery.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Just five years later, researchers in the COAPT trial reported that MitraClip repair also showed significant benefits for patients with symptomatic mitral regurgitation secondary to heart failure. The transcatheter repair device reduced all-cause mortality and hospitalization compared with medical therapy.
In response, the FDA recently broadened its approval of the device, making minimally invasive repair an option for more people with mitral regurgitation.
In this video, learn more about why expanded use of minimally invasive mitral valve surgery is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Cleveland Clinic and IBM leaders share insights, concerns, optimism about impacts
Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items
Dedicated committee and surgical fellowship strive for sustainability, energy efficiency, waste reduction
Next-generation mRNA vaccines are among the advancements likely to change healthcare this year
$50 million pledge will help remove sources of lead exposure from Cleveland homes
How to empower caregivers and engage patients in patient safety
The spine surgeon will oversee more than 125 staff physicians in his new role
Merlino rejoins Cleveland Clinic to help execute bold strategic vision